Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimu...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Sci Rep
Główni autorzy: Pizzuti, Laura, Marchetti, Paolo, Natoli, Clara, Gamucci, Teresa, Santini, Daniele, Scinto, Angelo Fedele, Iezzi, Laura, Mentuccia, Lucia, D’Onofrio, Loretta, Botticelli, Andrea, Moscetti, Luca, Sperati, Francesca, Botti, Claudio, Ferranti, Francesca, Buglioni, Simonetta, Sanguineti, Giuseppe, Di Filippo, Simona, di Lauro, Luigi, Sergi, Domenico, Catenaro, Teresa, Tomao, Silverio, Giordano, Antonio, Maugeri-Saccà, Marcello, Barba, Maddalena, Vici, Patrizia
Format: Artigo
Język:Inglês
Wydane: Nature Publishing Group UK 2017
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587713/
https://ncbi.nlm.nih.gov/pubmed/28878375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-10061-2
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy